Home Stock

Stock Research: Fulcrum Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Fulcrum Therapeutics

NMQ:FULC US3596161097
66
  • Value
    71
  • Growth
    46
  • Safety
    Safety
    59
  • Combined
    75
  • Sentiment
    53
  • 360° View
    360° View
    66
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecules for genetically defined rare diseases. It operates in the biopharmaceutical industry, focusing on therapies for conditions like sickle cell disease and inherited aplastic anemias (Diamond-Blackfan anemia, Shwachman-Diamond syndrome, and Fanconi anemia). In the last fiscal year, the company had 45 employees, a market cap of $425 million, $0 profits, and $80 million in revenue.

more

ANALYSIS: With an Obermatt 360° View of 66 (better than 66% compared with alternatives), overall professional sentiment and financial characteristics for the stock Fulcrum Therapeutics are above average. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Fulcrum Therapeutics. The consolidated Value Rank has an attractive rank of 71, which means that the share price of Fulcrum Therapeutics is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 71% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 59. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 53. But the consolidated Growth Rank has a low rank of 46, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 54 of its competitors have better growth. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Leverage
Country USA
Industry Pharmaceuticals
Size Small
Website fulcrumtx.com
Index
NASDAQ
Fulcrum Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
71 63 29 39
Growth
46 19 97 19
Safety
Safety
59 65 79 79
Sentiment
53 10 54 59
360° View
360° View
66 49 17 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
22 1 39 47
Opinions Change
50 50 72 50
Pro Holdings
n/a 25 54 73
Market Pulse
73 32 41 42
Sentiment
53 10 54 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
71 63 29 39
Growth
46 19 97 19
Safety Safety
59 65 79 79
Combined
75 54 82 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
48 54 3 11
Price vs. Earnings (P/E)
64 18 18 18
Price vs. Book (P/B)
65 73 62 54
Dividend Yield
1 1 1 1
Value
71 63 29 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
1 8 81 13
Profit Growth
35 89 60 37
Capital Growth
67 27 99 15
Stock Returns
46 17 61 83
Growth
46 19 97 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
76 100 100 73
Refinancing
58 92 83 81
Liquidity
20 1 6 6
Safety Safety
59 65 79 79

Similar Stocks

Discover high‑ranked alternatives to Fulcrum Therapeutics and broaden your portfolio horizons.

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews